X4 Pharmaceuticals, Inc — fact timeline

Kelly Gold was appointed as Class II director at X4 Pharmaceuticals, Inc.

“On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026.”

X4 Pharmaceuticals, Inc shareholders approved Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers.

“Proposal 4. Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers The Company’s stockholders approved, by a non-binding “say-on-pay” vote, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 70,932,142 20,692 5,420,569 6,474,104”

X4 Pharmaceuticals, Inc shareholders approved Approval of the Second Amended and Restated 2017 Equity Incentive Plan.

“Proposal 3. Approval of the Second Amended and Restated 2017 Equity Incentive Plan The Company’s stockholders approved the Second Amended and Restated 20217 Equity Incentive Plan. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 58,679,552 9,711 17,684,140 6,474,104”

X4 Pharmaceuticals, Inc shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.

“Proposal 2. Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 82,734,674 43,841 68,992 —”

X4 Pharmaceuticals, Inc shareholders approved Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders.

“Proposal 1. Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders The Company’s stockholders elected the persons listed below as director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows: Nominees For Withheld Broker non-votes Gary J. Bridger, Ph.D. 72,863,269 3,510,134 6,474,104 Françoise De Craecker 73,419,383 2,954,020 6,474,104 Murray W. Stewart, M.D. 71,679,834 4,693,569 6,474,104”

X4 Pharmaceuticals, Inc shareholders approved Approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers.

“Proposal 4. Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers The Company’s stockholders approved, by a non-binding “say-on-pay” vote, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 70,932,142 20,692 5,420,569 6,474,104”

X4 Pharmaceuticals, Inc shareholders approved Approval of the Second Amended and Restated 2017 Equity Incentive Plan.

“Proposal 3. Approval of the Second Amended and Restated 2017 Equity Incentive Plan The Company’s stockholders approved the Second Amended and Restated 20217 Equity Incentive Plan. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 58,679,552 9,711 17,684,140 6,474,104”

X4 Pharmaceuticals, Inc shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.

“Proposal 2. Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 82,734,674 43,841 68,992 —”

X4 Pharmaceuticals, Inc shareholders approved Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders.

“Proposal 1. Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders The Company’s stockholders elected the persons listed below as director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows: Nominees For Withheld Broker non-votes Gary J. Bridger, Ph.D. 72,863,269 3,510,134 6,474,104 Françoise De Craecker 73,419,383 2,954,020 6,474,104 Michael S. Wyzga 71,679,834 4,693,569 6,474,104”

X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.3 million for severance and other employee termination-related costs affecting the Company (reduce its workforce by approximately 50%).

“On September 17, 2025, X4 Pharmaceuticals, Inc. (the “Company” or “X4”) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long‐term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia. As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs.”

X4 Pharmaceuticals, Inc: Filed a certificate of amendment to effect a 1-for-30 reverse stock split of common stock, effective April 28, 2025 (effective 2025-04-28).

“On April 24, 2025, X4 Pharmaceuticals, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).”

X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.0 million for severance and other employee termination-related costs affecting the Company (43 employees, or approximately 30% of the Company’s employees).

“The Company estimates that it will incur charges of approximately $3.0 million for severance and other employee termination-related costs, primarily in the first quarter of 2025.”

X4 Pharmaceuticals, Inc completed a disposition for $105.0 million (closed 2024-05-08).

“On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.”

X4 Pharmaceuticals, Inc entered into Asset Purchase Agreement with not specified valued at $105,000,000 (effective 2024-05-08).

“On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.”

X4 Pharmaceuticals, Inc reported for the first quarter ended March 31, 2024 results: net income $51.8 million.

“X4 reported a net loss of $51.8 million for the first quarter ended March 31, 2024”

X4 Pharmaceuticals, Inc reported the full year ended December 31, 2023 results: net income net loss of $101.2 million.

“X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively”

X4 Pharmaceuticals, Inc reported the fourth quarter ended December 31, 2023 results: net income net loss of $19.1 million.

“X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively”

X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2023 results: net income Net Loss: X4 reported a net loss of $2.3 million for the third quarter ended September 30, 2023.

“X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.”

Keith Woods was appointed as Director at X4 Pharmaceuticals, Inc.

“On October 16, 2023, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Keith Woods as a member of the Company’s Board, effective immediately.”

X4 Pharmaceuticals, Inc reported financial results for the second quarter ended June 30, 2023.

“On August 10, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the second quarter ended June 30, 2023.”

X4 Pharmaceuticals, Inc amended credit facility of aggregate maximum borrowings of up to $115.0 million with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders at greater of (i) 10.15% or (ii) 3.15% plus the Wall Street Journal prime rate maturing October 1, 2026; provided, however , such maturity date will be extended to July 1, 2027 if the Amortization Date is extended.

“the Amendment upsizes the Company’s existing facilities and provides for a term loan facility of up to $115.0 million, including: (i) the $32.5 million Conversion Balance, which was deemed borrowed upon entering into the Amendment, (ii) a $22.5 million tranche, which the Company drew on the Closing Date of the Amendment”

X4 Pharmaceuticals, Inc amended Amendment to Second Amended and Restated Loan and Security Agreement with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders valued at aggregate maximum borrowings of up to $115.0 million (effective 2023-08-02).

“On August 2, 2023 (the “Closing Date”), X4 Pharmaceuticals, Inc. (the “Company”) and its subsidiary X4 Therapeutics, Inc. (together with the Company, the “Borrowers”) entered into an amendment (the “Amendment”) to the Existing Loan Agreement (as defined below) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, “Hercules”), which provides for aggregate maximum borrowings of up to $115.0 million”

X4 Pharmaceuticals, Inc shareholders approved Approval of the Company's Amended and Restated 2017 Employee Stock Purchase Plan at the 2023-06-13 meeting.

“The votes cast were as follows: For Against Abstain Broker Non-Votes 66,701,613 641,702 84,354 26,939,489”

X4 Pharmaceuticals, Inc shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation at the 2023-06-13 meeting.

“The votes cast were as follows: 1 Year 2 Years 3 Years Abstain 60,811,809 6,157,200 396,956 61,704”

X4 Pharmaceuticals, Inc shareholders approved Advisory Vote on the Compensation of the Named Executive Officers at the 2023-06-13 meeting.

“The votes cast were as follows: For Against Abstain Broker Non-Votes 59,263,769 7,988,869 175,031 26,939,489”

X4 Pharmaceuticals, Inc shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.

“The votes cast were as follows: For Against Abstain Broker Non-Votes 94,283,872 71,919 11,367 —”

X4 Pharmaceuticals, Inc shareholders approved Election of Directors at the 2023-06-13 meeting.

“The votes cast were as follows: Nominees For Withheld Broker Non-Votes Gary J. Bridger, Ph.D. 60,120,050 7,307,619 26,939,489 Francoise de Craecker 60,283,484 7,144,185 26,939,489 Murray W. Stewart, M.D. 60,138,639 7,289,030 26,939,489”

X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.

“X4 Pharmaceuticals Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023”

X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.

“On May 4, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the first quarter ended March 31, 2023.”

X4 Pharmaceuticals, Inc reported financial results for the fourth quarter and full year ended December 31, 2022.

“On March 21, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2022.”

X4 Pharmaceuticals, Inc incurred term loan of $32.5 million with Hercules Capital, Inc. at per annum rate equal to the greater of (i) 3.15% plus the Wall Street Journal pr maturing April 1, 2026.

“On January 6, 2023, X4 Pharmaceuticals, Inc. (the “Company”) and its subsidiary, X4 Therapeutics, Inc. (together with the Company, the “Borrowers”), entered into a Second Amended and Restated Loan and Security Agreement (the “Second A&R Loan Agreement”) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, “Hercules”), which provides for a term loan of $32.5 million (the “Term Loan”).”

X4 Pharmaceuticals, Inc amended Second Amended and Restated Loan and Security Agreement with Hercules Capital, Inc., Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1 valued at $32.5 million (effective 2023-01-06).

“On January 6, 2023, X4 Pharmaceuticals, Inc. (the “Company”) and its subsidiary, X4 Therapeutics, Inc. (together with the Company, the “Borrowers”), entered into a Second Amended and Restated Loan and Security Agreement (the “Second A&R Loan Agreement”) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, “Hercules”), which provides for a term loan of $32.5 million (the “Term Loan”).”

X4 Pharmaceuticals, Inc entered into Underwriting Agreement with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters valued at approximately $59.8 million (effective 2022-12-07).

“On December 7, 2022, X4 Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 52,300,000 shares of the Company’s common stock, pre-funded warrants to purchase 6,800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) and Class C warrants to purchase 29,550,000 shares of the Company’s common stock or Pre-Funded Warrants (the “Class C Warrants”) at a price to the public of $1.10 per share for common stock and accompanying Class C Warrant and $1.099 per Pre-Funded Warrant and accompanying Class C Warrant.”

X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2022 results: net income $21.6 million.

“X4 reported a net loss of $21.6 million for the third quarter of 2022, as compared to $20.2 million for the comparable period in 2021.”

Derek Meisner resigned as Chief Legal Officer and Corporate Secretary at X4 Pharmaceuticals, Inc.

“Derek Meisner provided X4 Pharmaceuticals, Inc. (the “Company”) with notice of his intent to resign from his position as Chief Legal Officer and Corporate Secretary of the Company, effective August 22, 2022, in order to pursue another opportunity.”

René Russo resigned as Director at X4 Pharmaceuticals, Inc.

“On November 11, 2021, René Russo resigned from the Board of Directors”

Francoise de Craecker was appointed as Director at X4 Pharmaceuticals, Inc.

“On October 14, 2021, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Francoise de Craecker as a member of the Company’s Board, effective immediately.”

Mary DiBiase was appointed as Chief Operating Officer at X4 Pharmaceuticals, Inc.

“On September 8, 2021, X4 Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mary DiBiase, Ph.D., age 60, as the Company’s Chief Operating Officer, effective as of September 8, 2021 (the “Effective Date”).”